Navigation Links
Halo Therapeutics' HT-100 Receives FDA's Orphan Designation for Duchenne Muscular Dystrophy
Date:1/4/2012

olio at Genzyme and founding multiple life science and healthcare companies. 

"We are in a race against time to find safe and effective therapies for boys with DMD," said Benjamin Seckler, MD, President of Charley's Fund. "Our partnering with Nash Avery Foundation to establish Halo Therapeutics is the next step in the DMD patient community's tireless effort to find such a therapy. We're excited to have Gene and Marc, experienced drug development and biopharma industry business professionals, leading the company."

HT-100 works by inhibiting the pathological fibrotic process in muscle and directly stimulating healthy muscle fiber regeneration. The company has acquired an extensive data package on HT-100 including results of numerous animal model studies, a comprehensive toxicology package, and human clinical data from multiple trials in healthy volunteers and select disease populations.

Planning is well underway for clinical evaluation of the compound. CEO Marc Blaustein said, "We're extremely pleased that HT-100 has received orphan drug designation. This adds momentum to the significant progress we've made since our founding, and we are pressing forward to initiate a Phase II clinical trial in 2012 to evaluate HT-100 in DMD patients."About Duchenne Muscular DystrophyDuchenne muscular dystrophy is caused by a mutation in the dystrophin gene, resulting in progressive muscle weakness. The disease manifests itself first in weakened skeletal muscles and eventually results in cardiac and pulmonary impairment. Corticosteroids are the current standard of care treatment for DMD.  While this treatment delays disease progression by several years, their prolonged use is typically associated with side effects and the treatment does not alter the ultimate outcome of the disease. Young men with Duchenne typically live into their twenties or early thirties.

About Halo TherapeuticsBased in Newton, Mass., Halo Therapeutics, LLC, is a clinical
'/>"/>

SOURCE Halo Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Echo Therapeutics Announces $3.6 Million Warrant Exercises
2. Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco
3. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
4. AuraSense Therapeutics Secures Series B Equity Investment
5. PTC Therapeutics Antibacterial Program Receives $5 Million Award from the Wellcome Trust
6. Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
7. Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
8. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
9. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
10. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
11. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
...  -- Ametros Financial Corporation and Ringler Medicare Solutions, ... a partnership to offer Professional Administration services to ... and Life Care Planning services currently offered by ... http://photos.prnewswire.com/prnh/20120406/CG83519 ) Insurers, third-party administrators and ...
... Inc. , a clinical-stage epigenetics oncology company, announced Arthur ... "We are delighted to have Art Pappas ... a former senior level pharmaceutical executive and as a highly ... chairman of the Syndax board of directors.  "As Syndax ...
Cached Medicine Technology:Ametros Financial and Ringler Medicare Solutions Announce Partnership to Provide Professional Administration Services 2Syndax Pharmaceuticals Appoints Arthur M. Pappas to Board of Directors 2
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
(Date:4/23/2014)... Washington, April 21, 2014 Five for-profit and ... of $1.25 million in Proof of Concept grants ... ideas into commercial products, the Life Sciences Discovery ... $300,000 Entrepreneur Mentoring Program grant to the Washington ... statewide advisory network to train the next generation ...
(Date:4/23/2014)... Time Physical Activity on Mobility Limitation in Old Age ... risk of mobility limitation in old age, whereas leisure-time ... a study which followed up 5,200 public sector employees ... Gerontology Research Center in Finland and the Finnish Institute ... repetitive, wears the body and lasts for several hours ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... Improved Health Care Access and ... ... health care experience for patients and,practitioners alike, AT&T (NYSE: T ... deliver the country,s first statewide health,information exchange., The Tennessee Information ...
... Acuo Technologies is a market,leading provider of comprehensive ... collaboration and migration services. Recently,there has been an ... the,increasing size of digital imaging archives caused by ... onset of new contributors,like digital pathology systems. Many ...
... DELHI, Feb. 25, 2008 A vaginal microbicide that incorporates ... HIV is safe for sexually active HIV-negative women to use ... clinical trial of tenofovir topical gel. Moreover, most of the ... the United States adhered to a regimen involving either daily ...
... 25 Every Step Counts Organization in,association with ... Forest Park will continue its efforts to celebrate ... will host "Walk In,Her Shoes" 2008, a unique ... --,St. Louis and Atlanta. Designer shoes featured in ...
... Can Leverage WLAN Infrastructure to Improve Patient Care with Visibility ... ... Personnel, WALTHAM, Mass., Feb. 25 Colubris ... and,service providers, today announced that the company is working with,AeroScout, Inc., ...
... Wireless ECG Devices Help Healthcare Organizations Deliver Clinical ... Data Faster ... Colubris Networks, the leading,global provider of intelligent wireless LANs ... Science Corporation,(Nasdaq: CSCX ) ( http://www.cardiacscience.com ), the ...
Cached Medicine News:Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 2Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 3Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 4Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 5Health News:Acuo Technologies(R) Offers Free Migration Archive License 2Health News:Acuo Technologies(R) Offers Free Migration Archive License 3Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 2Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 3Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 4Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 5Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 6Health News:Shoe Therapy Helps Survivors Celebrate Life After Abuse 2Health News:Colubris Partners with AeroScout to Enable Real-time Location Detection over Wireless Networks 2Health News:Colubris Partners with AeroScout to Enable Real-time Location Detection over Wireless Networks 3Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 3
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: